Table 4 Determinants of one-year mortality in ICU-survivors

Age (years)

67 [59–74]

68 [60–76]

1.008 [1.007–1.012]

0.03

Male gender

248 (58.5)

297 (58.2)

ICU admission

 2007–2012

174 (42.1)

210 (42.2)

 2013–2018

250 (58.1)

300 (58.8)

Type of cancer

 Lung

65 (15.3)

139 (27.3)

 Gastrointestinal

116 (27.4)

141 (27.7)

 Urologic

103 (24.3)

109 (21.4)

 Cutaneous

7 (1.7)

14 (2.8)

 Breast

48 (11.3)

26 (5.1)

 Lung cancer

65 (15.3)

139 (27.3)

1.44 [1.16–1.78]

 < 0.001

 Non-lung cancer

359 (84.7)

371 (72.7)

–

–

Stage

 Localized

181 (42.7)

73 (14.3)

–

–

 Advanced

99 (23.3)

104 (20.4)

–

–

 Metastatic

141 (33.3)

329 (64.5)

1.90 [1.53–2.37]

 < 0.001

Status

 Newly diagnosed

112 (26.4)

164 (32.2)

–

–

 Partial remission

118 (27.8)

80 (15.7)

–

–

 Complete remission

116 (27.4)

34 (6.7)

–

–

 In progression

78 (18.4)

232 (45.5)

1.39 [1.13–1.72]

0.002

Treatment in the past 3 months

 Chemotherapy

172 (40.5)

272 (53.3)

–

–

 Surgery

93 (21.9)

55 (10.8)

0.78 [0.57–1.05]

0.11

 Immunotherapy/targeted therapy

32 (7.5)

72 (14.1)

–

–

SOFA score

5 [3.75–7]

5 [4–7]

1.03 [0.99–1.06] ^a

0.05

Organ failure supports

 Invasive mechanical ventilation

121 (28.5)

140 (27.5)

–

–

 Non-invasive mechanical ventilation

54 (12.7)

59 (11.6)

–

–

 Inotropes/vasopressors

91 (21.5)

111 (21.8)

–

–

Renal replacement therapy

49 (11.6)

64 (12.5)

–

–

Admission patterns

 Non-specific complications

292 (68.9)

288 (56.5)

–

–

 Specific complications

67 (15.8)

178 (34.9)

1.75 [1.43–2.15]

 < 0.001

 Adverse event complications

65 (15.3)

44 (8.6)

–

–

 Drug-related adverse event

17 (4.0)

24 (4.7)

–

–

 Procedural adverse event

48 (11.3)

20 (3.9)

–

–

Decision to forgo life-sustaining therapy

11 (2.6)

120 (23.5)

3.21 [2.54–4.06]

 < 0.001